Los Angeles Capital Management LLC Trims Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Los Angeles Capital Management LLC lowered its stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 3.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 160,623 shares of the company’s stock after selling 5,355 shares during the period. Los Angeles Capital Management LLC’s holdings in Allogene Therapeutics were worth $718,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Swiss National Bank raised its stake in shares of Allogene Therapeutics by 3.0% during the 3rd quarter. Swiss National Bank now owns 192,400 shares of the company’s stock valued at $610,000 after purchasing an additional 5,600 shares during the period. Citigroup Inc. increased its position in shares of Allogene Therapeutics by 20.4% during the third quarter. Citigroup Inc. now owns 338,756 shares of the company’s stock valued at $1,074,000 after buying an additional 57,392 shares during the period. FMR LLC increased its position in shares of Allogene Therapeutics by 0.9% during the third quarter. FMR LLC now owns 25,143,931 shares of the company’s stock valued at $79,706,000 after buying an additional 225,976 shares during the period. Caxton Associates LP lifted its holdings in shares of Allogene Therapeutics by 590.0% in the third quarter. Caxton Associates LP now owns 480,104 shares of the company’s stock worth $1,522,000 after buying an additional 410,520 shares in the last quarter. Finally, Alps Advisors Inc. boosted its position in shares of Allogene Therapeutics by 15.4% in the third quarter. Alps Advisors Inc. now owns 123,718 shares of the company’s stock valued at $392,000 after acquiring an additional 16,515 shares during the period. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Insider Transactions at Allogene Therapeutics

In related news, Director Franz B. Humer sold 11,200 shares of the stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $2.34, for a total transaction of $26,208.00. Following the transaction, the director now owns 255,253 shares of the company’s stock, valued at approximately $597,292.02. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Arie Belldegrun bought 1,724,137 shares of the stock in a transaction dated Thursday, May 16th. The stock was bought at an average price of $2.90 per share, with a total value of $4,999,997.30. Following the purchase, the director now owns 1,724,137 shares in the company, valued at approximately $4,999,997.30. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Franz B. Humer sold 11,200 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $2.34, for a total value of $26,208.00. Following the transaction, the director now owns 255,253 shares in the company, valued at $597,292.02. The disclosure for this sale can be found here. Company insiders own 24.30% of the company’s stock.

Allogene Therapeutics Trading Up 2.4 %

ALLO opened at $2.61 on Tuesday. The stock has a market capitalization of $545.49 million, a P/E ratio of -1.46 and a beta of 0.86. The stock has a 50-day moving average price of $2.74 and a 200-day moving average price of $3.50. Allogene Therapeutics, Inc. has a 12-month low of $2.18 and a 12-month high of $6.05.

Allogene Therapeutics (NASDAQ:ALLO) last released its earnings results on Monday, May 13th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03. Allogene Therapeutics had a negative return on equity of 50.81% and a negative net margin of 223,139.98%. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.01 million. During the same quarter in the previous year, the company posted ($0.68) EPS. Allogene Therapeutics’s quarterly revenue was down 26.7% compared to the same quarter last year. On average, equities research analysts predict that Allogene Therapeutics, Inc. will post -1.5 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ALLO. Stifel Nicolaus upped their target price on shares of Allogene Therapeutics from $4.40 to $4.60 and gave the stock a “hold” rating in a report on Tuesday, May 14th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a research report on Friday, March 15th. Truist Financial restated a “buy” rating and set a $17.00 target price on shares of Allogene Therapeutics in a research report on Wednesday, May 15th. JPMorgan Chase & Co. decreased their target price on Allogene Therapeutics from $9.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 27th. Finally, Piper Sandler assumed coverage on Allogene Therapeutics in a research report on Friday, May 31st. They set an “overweight” rating and a $11.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.95.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).